Reportedly, Greece starts the rollout of the Johnson & Johnson (JNJ) COVID-19 vaccine on May 5 after Europe’s drug regulator backed its use, informed health authorities.
“We expect decisions by the CDC and FDA on Friday and then by our national committee on vaccinations in the following days. Vaccinations will begin on May 5,” stated Marios Themistocleous, secretary-general in charge of vaccinations.
Health Minister further informed that Greece will have vaccinated 2.5 million people in May and 4.0 million by June and to speed up the process, vaccinations will be done on weekends also and be available at private clinics. The authorities to open the vaccinations platform for those aged 30 to 39 years on April 27 for jabs with the AstraZeneca vaccine.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
